List view / Grid view
Researchers have discovered that the protein intersectin plays a crucial role in organising synaptic vesicles – enabling direct communication essential for learning and memory.
A new international framework introduces rigorous validity standards for the use of brain organoids and iPSC-derived models in studying neuropsychiatric disorders. These guidelines aim to accelerate drug discovery and bring precision treatments closer to reality.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Scientists from Fudan University have halted the progression of ALSP, a rare and fatal brain disease, using a pioneering microglia replacement therapy - marking the first effective clinical approach to tackling the disease.
Repurposing existing FDA-approved drugs could make nanomedicines safer by reducing harmful immune reactions, according to new research.
Immune cells in the brain called microglia may hold the key to improving blood flow and tackling diseases like Alzheimer’s, new research from the University of Virginia suggests.
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
Researchers at Tel Aviv University have developed a new mouse model that accurately mimics a rare and severe genetic disorder caused by mutations in the GRIN2D gene – allowing for study of the disease’s progression and the testing of potential drug therapies.
A hormone produced in the gut, FGF19, has been shown to act directly on the brain to boost energy expenditure, burn fat and improve blood sugar control in obese mice - offering a potential route for developing new obesity therapies.
Scientists at the University of Sydney have discovered a malfunctioning brain protein linked to Parkinson’s - which could lead to new therapies for the debilitating condition in the future.
A new study reveals that blocking the enzyme ST6Gal-I reduces toxic plaque buildup in Alzheimer’s disease by suppressing BACE1 expression - highlighting a new target for future treatment strategies.
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
SynaptixBio has selected its lead drug candidate, SB H-19642, for clinical trials to treat H-ABC - a rare, fatal neurodegenerative disease with no current cure.
Scientists have developed a simple- 3D mouse tissue model to study how the nose regenerates smell-sensing neurons. The goal is to create an organoid system that can be used to screen potential therapies for smell loss.
Researchers at the University of Alabama have identified reelin, a glycoprotein known for its role in brain development, as a key regulator of neurons in the brain's reward centre, potentially making way for targeted therapies against cocaine use.
